Randall J. Smith

Randall J. Smith

Auto-generated profile, based on publicly available information

Randall J. Smith

Department of Thoracic Surgery

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Biomaterials
Verified
Journal Article
Closed access
MKMaxwell T. Koobatian
Maxwell T. Koobatian
SRSindhu Row
Sindhu Row
RJRandall J. Smith Jr
Randall J. Smith Jr
CKCarmon Koenigsknecht
Carmon Koenigsknecht
Stelios T. AndreadisStelios T. Andreadis
Stelios T. Andreadis
DSDaniel D. Swartz
Daniel D. Swartz

1 May 2015 in Biomaterials
Verified
Journal Article
Open access
RSRandall J. Smith
Randall J. Smith
MKMaxwell T. Koobatian
Maxwell T. Koobatian
ASAref Shahini
Aref Shahini
DSDaniel D. Swartz
Daniel D. Swartz
Stelios T. AndreadisStelios T. Andreadis
Stelios T. Andreadis
We demonstrate the ability of immobilized vascular endothelial growth factor (VEGF) to capture endothelial cells (EC) with high specificity under fluid flow. To this end, we engineered a surface consisting of heparin bound to poly-l-lysine to permit immobilization of VEGF through the C-terminal heparin-binding domain. The immobilized growth factor retained its biological activity as shown by proliferation of EC and prolonged activation of KDR signaling. Using a microfluidic device we assessed the ability to capture EC under a range of shear stresses from low (0.5 dyne/cm(2)) to physiological (15 dyne/cm(2)). Capture was significant for all shear stresses tested. Immobilized VEGF was highly selective for EC as evidenced by significant capture of human umbilical vein and ovine pulmonary artery EC but no capture of human dermal fibroblasts, human hair follicle derived mesenchymal stem cells, or mouse fibroblasts. Further, VEGF could capture EC from mixtures with non-EC under low and high shear conditions as well as from complex fluids like whole human blood under high shear. Our findings may have far reaching implications, as they suggest that VEGF could be used to promote endothelialization of vascular grafts or neovascularization of implanted tissues by rare but continuously circulating EC.

10 January 2019 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
RSRandall J. Smith
Randall J. Smith
TYTai Yi
Tai Yi
BNBita Nasiri
Bita Nasiri
CBChristopher K. Breuer
Christopher K. Breuer
Stelios T. AndreadisStelios T. Andreadis
Stelios T. Andreadis
Recently, our group demonstrated that immobilized VEGF can capture flowing endothelial cells (ECs) from the blood in vitro and promote endothelialization and patency of acellular tissue–engineered vessels (A‐TEVs) into the arterial system of an ovine animal model. Here, we demonstrate implantability of submillimeter diameter heparin and VEGF‐decorated A‐TEVs in a mouse model and discuss the cellular and immunologic response. At 1 mo postimplantation, the graft lumen was fully endothelialized, as shown by expression of EC markers such as CD144, eNOS, CD31, and VEGFR2. Interestingly, the same cells coexpressed leukocyte/macrophage (Mϕ) markers CD14, CD16, VEGFR1, CD38, and EGR2. Notably, there was a stark difference in the cellular makeup between grafts containing VEGF and those containing heparin alone. In VEGF‐containing grafts, infiltrating monocytes (MCs) converted into anti‐inflammatory M2‐Mϕs, and the grafts developed well‐demarcated luminal and medial layers resembling those of native arteries. In contrast, in grafts containing only heparin, MCs converted primarily into M1‐Mϕs, and the endothelial and smooth muscle layers were not well defined. Our results indicate that VEGF may play an important role in regulating A‐TEV patency and regeneration, possibly by regulating the inflammatory response to the implants.—Smith, R. J., Jr., Yi, T., Nasiri, B., Breuer, C. K., Andreadis, S. T. Implantation of VEGF‐functionalized cell‐free vascular grafts: regenerative and immunological response. FASEB J. 33, 5089–5100 (2019). www.fasebj.org

1 June 2019 in Acta Biomaterialia
Verified
Journal Article
Closed access
KNKihoon Nam
Kihoon Nam
SDSpencer M. Dean
Spencer M. Dean
CBCallie T. Brown
Callie T. Brown
RSRandall J. Smith
Randall J. Smith
PLPedro Lei
Pedro Lei
Olga BakerOlga Baker
Olga Baker

29 June 2016 in Tissue Engineering Part A
Verified
Journal Article
Closed access
XYXue Yuan
Xue Yuan
RSRandall J. Smith
Randall J. Smith
HGHuiyan Guan
Huiyan Guan
CICiprian N. Ionita
Ciprian N. Ionita
PKParag Khobragade
Parag Khobragade
SYShuying Yang
Shuying Yang
Bone is a highly vascularized tissue and efficient bone regeneration requires neovascularization, especially for critical-sized bone defects. We developed a novel hybrid biomaterial comprising nanocalcium sulfate (nCS) and fibrin hydrogel to deliver mesenchymal stem cells (MSCs) and angiogenic factors, vascular endothelial growth factor (VEGF) and fibroblast growth factor 9 (FGF9), to promote neovascularization and bone formation. MSC and growth factor(s)-loaded scaffolds were implanted subcutaneously into mice to examine their angiogenic and osteogenic potential. Micro CT, alkaline phosphatase activity assay, and histological analysis were used to evaluate bone formation, while immunohistochemistry was employed to assess neovessel formation. The presence of fibrin preserved the nCS scaffold structure and promoted de novo bone formation. In addition, the presence of bone morphogenic protein 2-expressing MSC in nCS and fibrin hydrogels improved bone regeneration significantly. While FGF9 alone had no significant effect, the combination FGF9 and VEGF conjugated in fibrin enhanced neovascularization and bone formation more than 4-fold compared to nCS with MSC. Overall, our results suggested that the combination of nCS (to support bone formation) with a fibrin-based VEGF/FGF9 release system (support vascular formation) is an innovative and effective strategy that significantly enhanced ectopic bone formation in vivo .

1 July 2016 in Science Advances
Verified
Journal Article
Open access
PDF file
YLYi Li
Yi Li
MBMarie Beitelshees
Marie Beitelshees
LFLei Fang
Lei Fang
AHAndrew Hill
Andrew Hill
MAMahmoud Kamal Ahmadi
Mahmoud Kamal Ahmadi
Blaine PfeiferBlaine Pfeifer
Blaine Pfeifer
The type and potency of an immune response provoked during vaccination will determine ultimate success in disease prevention. The basis for this response will be the design and implementation of antigen presentation to the immune system. Whereas direct antigen administration will elicit some form of immunological response, a more sophisticated approach would couple the antigen of interest to a vector capable of broad delivery formats and designed for heightened response. New antigens associated with pneumococcal disease virulence were used to test the delivery and adjuvant capabilities of a hybrid biological-biomaterial vector consisting of a bacterial core electrostatically coated with a cationic polymer. The hybrid design provides (i) passive and active targeting of antigen-presenting cells, (ii) natural and multicomponent adjuvant properties, (iii) dual intracellular delivery mechanisms, and (iv) a simple formulation mechanism. In addition, the hybrid format enables device-specific, or in situ, antigen production and consolidation via localization within the bacterial component of the vector. This capability eliminates the need for dedicated antigen production and purification before vaccination efforts while leveraging the aforementioned features of the overall delivery device. We present the first disease-specific utilization of the vector toward pneumococcal disease highlighted by improved immune responses and protective capabilities when tested against traditional vaccine formulations and a range of clinically relevant Streptococcus pneumoniae strains. More broadly, the results point to similar levels of success with other diseases that would benefit from the production, delivery, and efficacy capabilities offered by the hybrid vector.